CardioComm Solutions Launches New GEM(TM) Mobile Universal ECG App Expanding ECG Reporting Services Across Global Markets

FDA Approval of New Version of GEMS Mobile ECG App Will Result in Growing Number of Partnerships with ECG Device Manufacturers

Toronto, Ontario--(Newsfile Corp. - March 25, 2019) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, announces the release of a new version of the Company's recently cleared US Food and Drug Administration ("FDA") GEMS™ Mobile ECG app. The new version is branded as the GEMS™ Universal ECG ("GEMS™ Universal") and is capable of connecting with multiple manufacturer's consumer and prescription ECG devices sold globally.

The GEMS™ Universal ECG app allows users access to CardioComm's fee-for-use SMART Monitoring ECG reading service, through which they can request a review of their ECG(s) to confirm the presence or absence of arrhythmias. GEMS™ Universal will be available for a fee of $6 per month, which will include one free ECG triage. GEMS Universal will also be available under an annual fee of $69, with 12 free triage reports included. These reports may be requested at any time during a renewable one year subscription. CardioComm device partners will share in revenues generated from downloads of the app and from SMART Monitoring ECG readings.

GEMS™ Universal is a slimmed-down version of the Company's Health Canada-approved, FDA-cleared and CE Mark-certified, hospital-based Global ECG Management System (GEMS^TM). GEMS™ Universal will be marketed for use with non-HeartCheck™ branded ECG devices, and will allow users the ability to generate unlimited, medical-grade ECG PDFs in near-real-time.

The first release of the GEMS™ Universal ECG is compatible with several OEM and private label devices, including those manufactured by Contec Medical Systems and BORSAM Biomedical Instruments. These manufacturers provide CardioComm with access to a global audience of ECG device users in regions where other companies have already established hardware sales.

The GEMS™ ECG Universal ECG app is scheduled to be available on the App Store and Google Play in April.

For further updates regarding GEMS^TM Mobile ECG device partnerships please see the Company's websites at www.theheartcheck.com and www.cardiocommsolutions.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43646